Xenitra Raises $1.25 Million to Drive OTC and Digital Growth Plans
Xenitra Limited (ASX: XEN) has secured commitments to raise $1.25 million through a placement aimed at supporting the company’s next phase of expansion. The funding was backed by institutional, professional, and sophisticated investors, reflecting continued market interest in the company’s growth strategy. Under the placement, Xenitra will issue up to 416.7 million fully paid ordinary shares priced at $0.003 each. Investors will also receive one unquoted option for every two shares issued, with the options exercisable at $0.004 and expiring in April 2028, subject to shareholder approval.
The company plans to use the proceeds to accelerate the expansion of its over-the-counter medicines business and further develop the OPAL RWA token ecosystem across additional brands. Funds will also support working capital requirements, infrastructure improvements, and placement-related costs.
Novus Capital acted as the sole lead manager for the raising and will receive management and selling fees as part of the transaction. Xenitra stated that the capital injection will strengthen its ability to scale operations and pursue broader commercial opportunities in both healthcare and digital asset sectors.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Xenitra Raises $1.25 Million to Drive OTC and Digital Growth Plans
Xenitra Limited (ASX: XEN) has secured commitments to raise $1.25 million through a placement aimed at supporting the company’s next phase of expansion. The funding was backed by institutional, professional, and sophisticated investors, reflecting continued market interest in the company’s growth strategy. Under the placement, Xenitra will issue up to 416.7 million fully paid ordinary shares priced at $0.003 each. Investors will also receive one unquoted option for every two shares issued, with the options exercisable at $0.004 and expiring in April 2028, subject to shareholder approval.
The company plans to use the proceeds to accelerate the expansion of its over-the-counter medicines business and further develop the OPAL RWA token ecosystem across additional brands. Funds will also support working capital requirements, infrastructure improvements, and placement-related costs.
Novus Capital acted as the sole lead manager for the raising and will receive management and selling fees as part of the transaction. Xenitra stated that the capital injection will strengthen its ability to scale operations and pursue broader commercial opportunities in both healthcare and digital asset sectors.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au